Vivimed Labs Valuation
Is VIVIMEDLAB undervalued compared to its fair value, analyst forecasts and its price relative to the market?
Valuation Score
4/6Valuation Score 4/6
Below Fair Value
Significantly Below Fair Value
Price-To-Sales vs Peers
Price-To-Sales vs Industry
Price-To-Sales vs Fair Ratio
Analyst Forecast
Share Price vs Fair Value
What is the Fair Price of VIVIMEDLAB when looking at its future cash flows? For this estimate we use a Discounted Cash Flow model.
Below Fair Value: VIVIMEDLAB (₹4.95) is trading below our estimate of fair value (₹15.18)
Significantly Below Fair Value: VIVIMEDLAB is trading below fair value by more than 20%.
Key Valuation Metric
Which metric is best to use when looking at relative valuation for VIVIMEDLAB?
Key metric: As VIVIMEDLAB is unprofitable we use its Price-To-Sales Ratio for relative valuation analysis.
| What is VIVIMEDLAB's PS Ratio? | |
|---|---|
| PS Ratio | 0.2x |
| Sales | ₹1.73b |
| Market Cap | ₹410.42m |
| Key Statistics | |
|---|---|
| Enterprise Value/Revenue | 2.4x |
| Enterprise Value/EBITDA | -2.7x |
| PEG Ratio | n/a |
Price to Sales Ratio vs Peers
How does VIVIMEDLAB's PS Ratio compare to its peers?
| Company | Forward PS | Estimated Growth | Market Cap |
|---|---|---|---|
| Peer Average | 4.1x | ||
540694 ANG Lifesciences India | 0.6x | n/a | ₹594.4m |
524768 Emmessar Biotech & Nutrition | 9.9x | n/a | ₹226.0m |
524414 Norris Medicines | 5.2x | n/a | ₹215.3m |
538965 Concord Drugs | 0.7x | n/a | ₹357.4m |
VIVIMEDLAB Vivimed Labs | 0.2x | n/a | ₹410.4m |
Price-To-Sales vs Peers: VIVIMEDLAB is good value based on its Price-To-Sales Ratio (0.2x) compared to the peer average (2x).
Price to Sales Ratio vs Industry
How does VIVIMEDLAB's PS Ratio compare vs other companies in the IN Pharmaceuticals Industry?
| 13 Companies | Price / Sales | Estimated Growth | Market Cap |
|---|---|---|---|
| Industry Avg. | 3.0x | 11.3% | |
VIVIMEDLAB Vivimed Labs | 0.2x | n/a | US$4.92m |
NECLIFE Nectar Lifesciences | 0.5x | n/a | US$90.98m |
539561 Remedium Lifecare | 0.07x | n/a | US$28.97m |
| 13 Companies | Estimated Growth | Market Cap | |
|---|---|---|---|
| Industry Avg. | 3.0x | 17.7% | |
VIVIMEDLAB Vivimed Labs | 0.2x | n/a | US$4.92m |
Price-To-Sales vs Industry: VIVIMEDLAB is good value based on its Price-To-Sales Ratio (0.2x) compared to the Indian Pharmaceuticals industry average (2.3x).
Price to Sales Ratio vs Fair Ratio
What is VIVIMEDLAB's PS Ratio compared to its Fair PS Ratio? This is the expected PS Ratio taking into account the company's forecast earnings growth, profit margins and other risk factors.
| Fair Ratio | |
|---|---|
| Current PS Ratio | 0.2x |
| Fair PS Ratio | n/a |
Price-To-Sales vs Fair Ratio: Insufficient data to calculate VIVIMEDLAB's Price-To-Sales Fair Ratio for valuation analysis.
Analyst Price Targets
What is the analyst 12-month forecast and do we have any statistical confidence in the consensus price target?
Analyst Forecast: Insufficient data to show price forecast.
Discover undervalued companies
Bal Pharma
₹2.2b
Manufactures and markets pharmaceutical formulations and active pharmaceutical ingredients (APIs) in India and internationally.
BALPHARMA
₹134.50
7D
11.6%
1Y
27.4%
Caplin Point Laboratories
₹147.7b
Engages in the development, production, marketing, and export of generic pharmaceutical formulations and branded products in India.
CAPLIPOINT
₹1,942.80
7D
-0.4%
1Y
58.1%
Venus Remedies
₹4.0b
Engages in the pharmaceutical business in India and internationally.
VENUSREM
₹298.65
7D
-1.3%
1Y
-16.9%